Cipla's Umang Vohra: Ramped-up production by 5x for COVID-19 drugs like Remdesivir; Investment in ABCD Tech to add to digital channel transformation

The company's MD and Group CEO said that Cipla sustained strong EBITDA margins through the year, recording the highest ever margin of 22.5% in FY21.

from India Infoline News Service https://ift.tt/3zYiWV7